Truncated L1 protein of human papillomavirus type 58
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Aug 22, 2017
Issued Date -
N/A
app pub date -
Mar 1, 2016
filing date -
Jul 16, 2010
priority date (Note) -
In Force
status (Latency Note)
Importance
Loading Importance Indicators... 
Abstract
Provided are an N-terminal truncated L1 protein of the Human Papillomavirus Type 58, a coding sequence and preparation method thereof, and a virus-like particle comprising the protein. Uses of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine are further provided. The pharmaceutical composition or vaccine is used for prevention of HPV infection and a disease caused by HPV infection.
First Claim
Other Claims data not available
Family
Loading Family data...
International Classification(s)
- 2016 Application Filing Year
- A61K Class
- 19101 Applications Filed
- 13019 Patents Issued To-Date
- 68.16 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 0 Citation Count
- A61K Class
- 0 % this patent is cited more than
- 8 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Feb 22, 2025 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Feb 22, 2029 |
